Cellmid launch hair loss product to vast US market
Published 04-NOV-2016 09:44 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Three months of pre-launch activities culminated today in Cellmid Limited’s (ASX:CDY) launch of their évolis® hair loss range in the US.
The company’s wholly owned subsidiary, Avangen Limited, will commence online pre-sales on November 7 with product shipping to kick off on December 5.
The evolis® hair loss range is a key part of Cellmid’s business plan, which has proven to be a lead revenue driver for the company in Australia and Japan. The launch of the products in the US presents a significant opportunity for CDY to exploit the US$3.5 billion hair loss market, by far the biggest in the world.
Industry and influencers key to building the buzz
In the lead up to launch, Cellmid have focused on manufacturing and branding for the évolis® range, as well as pre-launch promotions. ‘évolis® REVERSE’ was introduced to beauty editors of fashion and lifestyle magazines, as well as influencers and bloggers.
Reaching out to key media influencers has won CDY various commitments to both product trials and editorial coverage from now up till June 2017. Advangen also introduced the product range to 250 top US hair salon chains in an industry meeting on hair loss in Atlanta, GA.
The launch, with distribution partner Colour Collective, is the company’s most significant undertaking yet, and is predicted to boost near-term profitability.
How profitable is yet to be determined so seek professional financial advice and consider all facts before making an investment decision.
Managing Director of Colour Collective, Kerry Yates said: “évolis® is poised to disrupt the $3.5 billion hair loss market in the US where over 80 million people suffer from the condition”.
The évolis® range was launched in Australia in June this year. Since then, CDY has clocked up an impressive $1,022,913 in sales for Q1 FY2017.
Advangen is one of CDY’s three wholly owned subsidiaries; others are Lyramid and Kinera, developing treatments for kidney disease and heart failure.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
